Topical pharmaceutical composition

A method of treating recurrent herpetic episodes in humans comprising topically administering a therapeutic amount of a composition comprising 0.1-25 percent by weight of a C20-C28 aliphatic alcohol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant to a human in need thereof.

A method of treating symptoms associated with a cold sore lesion comprising topically administering a therapeutic amount of a composition comprising 0.1-25 percent by weight of a C20-C28 aliphatic alcohol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant to a person in need thereof.

A therapeutic composition for topical application to a herpes virus lesion comprising 0.1-25 percent by weight of a C20-C28 aliphatic alcohol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant, which composition forms a film on the lesion maintaining the composition on the lesion until removed.

A method for reducing pain associated with surface inflammation of the skin or membrane, comprising topically administering to an inflamed surface of the skin or membrane, a therapeutic amount of a composition comprising 0.1-25 percent by weight of a C20-C28 aliphatic alcohol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant.

A method of protecting a cold sore lesion from physical disturbance during healing, comprising topically administering to the lesion a therapeutic amount of a composition comprising 0.1-25 percent by weight of n-docosanol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant.

A regimen for treating recurrent herpetic episodes in humans comprising topically administering a therapeutic amount of a composition comprising 0.1-25 percent by weight of a C20-C28 aliphatic alcohol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant to a human in need thereof;

• allowing the composition to remain undisturbed at the site of application for between 6 and 10 hours;
• removing the composition;
• and repeating the procedure over the course of at least 4 days.

A regimen for reducing the healing time of a lesion associated with recurrent herpetic episodes in humans, comprising topically administering to the lesion a therapeutic amount of a composition comprising 0.1-25 percent by weight of a C20-C28 aliphatic alcohol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant to a human in need thereof;

• allowing the composition to remain undisturbed at the site of application for between 6 and 10 hours;
• removing the composition;
• and repeating the procedure over the course of at least 4 days.

A regimen for reducing pain associated with surface inflammation of the skin or membrane, comprising topically administering to an inflamed surface of the skin or membrane, a therapeutic amount of a composition comprising 0.1-25 percent by weight of a C20-C28 aliphatic alcohol, a plasticizer, a film-forming polymer and a sugar-based ester surfactant to a human in need thereof;

• allowing the composition to remain undisturbed for between 6 and 10 hours;
• removing the composition;
• and repeating the procedure over the course of at least 4 days.

A therapeutic composition for topical application to skin and membranes comprising 10.0 percent by weight of a C20-C28 aliphatic alcohol, 1.0 percent by weight of a plasticizer, 5.0 percent by weight of a film-forming polymer and 5.0 percent by weight of a sugar-based ester surfactant.

A therapeutic composition for topical application to skin and membranes comprising 10.0 percent by weight of n-docosanol, 1.0 percent by weight of a plasticizer, 5.0 percent by weight of a film-forming polymer and 5.0 percent by weight of a sugar-based ester surfactant.

A therapeutic composition for topical application to skin and membranes consisting essentially of 8.00% w/w of mineral oil, 10.00% w/w of n-docosanol, 65.10% w/w water, 5.00% w/w of sucrose stearate/distearate, 5.00% w/w of propylene glycol, 2.70% w/w of benzyl alcohol, 0.90% w/w of glycerol, 1.00% w/w of titanium dioxide, and 2.30% w/w of polyvinylpyrrolidone.